Incyte today announced that the U.S. Food and Drug Administration has approved Pemazyre ®, a selective fibroblast growth factor receptor inhibitor, for the treatment of adults with relapsed or ...

The prognosis for patients with myeloid/lymphoid neoplasms with FGFR1 rearrangements is poor, and treatment options are limited. In a phase II study of these patients, the overall complete response ...

Mixed phenotype acute leukemia has qualities of both lymphoid and myeloid leukemias. These mixed qualities make it very difficult to diagnose and treat. The outlook for people with this type of ...

At the recent American Society of Hematology annual meeting, researchers presented real-world outcomes for patients with ...

Biphenotypic leukemia is a mixed type of leukemia that originates in both lymphoid and myeloid cells. It typically has a poorer outlook than other acute leukemias. A stem cell transplant may improve ...

Lymphoid-derived conventional dendritic cells (L-cDCs) may play a unique function associated with immune suppression and allergy induction, as reported by researchers from Japan. Long thought to arise ...

Since the development of the super immunodeficient CIEA NOG mouse® in the early 2000s enabled improved humanized immune system (HIS) mice, HIS models have been widely adopted in immuno-oncology ...